


Plenary Session

State-of-the-Art Lecture

Genetics of Obesity to be Subject of State-of-the-Art Lecture



Stephen O'Rahilly, MD

Stephen O'Rahilly, MD, will speak on "The Causes and Consequences of Obesity: Lessons from Genetics" in a state-of-the-art lecture on Thursday, Nov. 17.

Dr. O'Rahilly is professor of clinical biochemistry and medicine and head of the department of clinical biochemistry at the University of Cambridge and honorary consultant physician at Addenbrooke's Hospital in Cambridge, UK. He is active in clinical practice and in teaching medical students.

In his research, he has sought to better understand the molecular mechanisms leading to diabetes, obesity, and related metabolic and endocrine disorders. Dr. O'Rahilly led the establishment of the Wellcome Trust-MRC Institute of Metabolic Science, which he co-directs along with directing the institute's metabolic diseases unit. He is scientific director of the National Institute for Health Research's Cambridge Biomedical Research Centre.

Dr. O'Rahilly is currently president of the Society for Endocrinology. He served as chair of the UK Medical Research Society and as a member of the biological awards committee of the Royal Society.

He was the founding editor of *Cell Metabolism, Disease Models & Mechanisms*, and *EMBO Molecular Medicine*, where he still serves on the editorial board. He currently serves on the editorial board of *Reviews in Endocrine & Metabolic Disorders* and has been on the boards of the *Quarterly Journal of Medicine*, *Diabetic Medicine*, and *PLOS Biology*.

Dr. O'Rahilly has won many national and international awards, including the Heinrich Wieland Prize, the Inbev Baillet Latour Prize, the Zülch Prize, and the first European Association for the Study of Diabetes/Novo Nordisk Foundation Diabetes Prize for Excellence. He was elected to the Royal Society in 2003 and as a foreign associate of the US National Academy of Sciences in 2011. He is an honorary member of the German Society for Internal Medicine. He was appointed a Knight Bachelor in 2013.

He received his medical degree from the National University of Ireland and undertook postgraduate training in London, Oxford, and Boston before setting up his laboratory in Cambridge in 1991.

Blagg Lectureship to Cover Patients' Hospital Transition Process



David O. Meltzer, MD, PhD

David O. Meltzer, MD, PhD, will discuss "Optimizing Transitions for Our Patients in and out of the Hospital: Justifying Theory and Practice" in the Christopher R. Blagg, MD, Lectureship in Renal Disease and Public Policy on Thursday, Nov. 17.

Dr. Meltzer is chief of the section of hospital medicine, director of the Center for Health and the Social Sciences, director of the UChicago Urban Health Lab, and chair of the Committee on Clinical and Translational Science at the University of Chicago. He is also the Fannie L. Pritzker Professor in the department of medicine, the Harris School of Public Policy Studies, and the department of economics.

Dr. Meltzer's research explores problems in health economics and public policy with a focus on the theoretical foundations of medical cost-effectiveness analysis and the cost and quality of hospital care. He has performed randomized trials on the use of hospitalists to specialize in inpatient care. He is currently leading a Center for Medicare and Medicaid Innovation challenge award to study the effects of improved continuity in the doctor-patient relationship between the inpatient and outpatient setting, focusing on the costs and outcomes of care for frequently hospitalized Medicare patients.

He helped lead the formation of the Chicago Learning Effectiveness Advancement Research Network (Chicago LEARN), which helped pioneer collaboration of Chicago-area academic medical centers in hospital-based comparative effectiveness research. He was also a leader of the Chicago Area Patient Centered Outcomes Research Network (CAPriCORN), which was funded by the Patient-Centered Outcomes Research Institute (PCORI).

Dr. Meltzer is a research associate of the National Bureau of Economic Research, an elected member of the American Society for Clinical Investigation, and past president of the Society for Medical Decision Making. He has served on several Institute of Medicine panels, including one examining US organ allocation policy.

He also has served on the Advisory Committee on Healthy People 2020 of the US Department of Health and Human Services, on the PCORI methodology committee, as a council member of the National Institute for General Medical Studies, and as a health economics adviser for the Congressional Budget Office. Dr. Meltzer has received many awards, including the Eugene Garfield Award from Research America, the Eisenberg Excellence in Mentoring Award from the Agency for Healthcare Research and Quality, and the Learning Healthcare System Award from the Association of American Medical Colleges. He is a member of the National Academy of Medicine.

Dr. Meltzer received both his MD and his PhD in economics from the University of Chicago and completed his residency in internal medicine at Brigham and Women's Hospital in Boston.

Genetics of Renal Diseases to Be Outlined in Winn Lecture



Cheryl Ann Winkler, PhD

Apioneer in investigations to reveal the host's genetic architecture related to infectious diseases and associated co-morbidities will speak on "GWAS in Nephrology." Cheryl Ann Winkler, PhD, will deliver the Michelle P. Winn, MD, Endowed Lectureship on Thursday, Nov. 17.

Dr. Winkler is a senior investigator in the basic research laboratory and head of the molecular genetic epidemiology section at the National Cancer Institute. She led the genetics team that used admixture mapping to identify the region of chromosome 22 harboring *MYH9* and *APOL1*, two genes associated with kidney diseases. That research identified *MYH9* as a major susceptibility gene for common etiologies of chronic and end stage renal disease and *APOL1*'s role in the greatly increased susceptibility of African Americans to HIV-associated nephropathy and focal segmental glomerulosclerosis (FSGS).

APOL1 variants are predictors of chronic kidney disease and markers for progression, but they also protect against the tropical disease trypanosomiasis, commonly known as sleeping sickness. Her team is now identifying the spectrum of phenotypes associated with *APOL1* risk alleles in American and African cohorts and investigating the pathophysiological mechanism leading to glomerular injury. They are studying the influence of *APOL1* risk variants on living kidney donors and on kidney graft survival in African Americans. A goal of this research is to develop biomarkers for diagnostics and prognostics and to identify drug targets to treat kidney diseases.

Her team is also participating in the Family Investigation of Nephropathy and Diabetes (FIND) consortium, with the goal of discovering genetic risk factors for diabetic nephropathy and end stage renal disease.

Dr. Winkler is author or co-author of more than 160 publications. She is also a senior principal scientist with Leidos Biomedical Research at the Frederick National Laboratory for Cancer Research as well as an honorary professor in the school of clinical medicine at the University of KwaZulu-Natal in South Africa.

Dr. Winkler received a master's degree in genetics and a PhD in immunogenetics from the University of Maryland, College Park. She completed her dissertation research and a postdoctoral fellowship at the laboratory of genomic diversity at the National Cancer Institute.